Thalys Medical Technology Group Corporation Stock price

Equities

603716

CNE1000030C3

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
8.07 CNY +6.04% Intraday chart for Thalys Medical Technology Group Corporation -23.29% -27.23%
Sales 2021 2.6B 360M Sales 2022 2.31B 320M Capitalization 2.12B 293M
Net income 2021 -49M -6.78M Net income 2022 -154M -21.31M EV / Sales 2021 1.51 x
Net Debt 2021 1.11B 154M Net Debt 2022 1.01B 140M EV / Sales 2022 1.35 x
P/E ratio 2021
-57 x
P/E ratio 2022
-13.9 x
Employees 1,474
Yield 2021 *
-
Yield 2022
-
Free-Float 75.07%
More Fundamentals * Assessed data
Dynamic Chart
Lin Zhonggang agreed to acquire a 43.5% stake in Heilongjiang Thalys Medical Technology Co., Ltd. from Thalys Medical Technology Group Corporation for CNY 1.5 million CI
An undisclosed buyer acquired a 51% stake in Guangdong Thalys Medical Technology Co., Ltd. Thalys Medical Technology Group Corporation CI
An unknown buyer acquired 51% stake in Chengdu Thalys Medical Technology Co., Ltd. from Thalys Medical Technology Group Corporation for CNY 1.02 million. CI
An undisclosed buyer acquired 51% stake in Shanxi Thalys Medical Technology Co., Ltd. from Thalys Medical Technology Group Corporation for CNY 1.53 million. CI
Shanxi Tianli Hengde Pharmaceutical Technology Co., Ltd. signed an equity transfer agreement to acquire 51% stake in Shanxi Jianghe Tonghui Medical Equipment Co., Ltd. from Thalys Medical Technology Group Corporation for CNY 0.55 million. CI
Thalys Medical Technology Group Corporation announces an Equity Buyback for CNY 20 million worth of its shares. CI
Thalys Medical Technology Group Corporation authorizes a Buyback Plan. CI
Thalys Medical Technology Group Corporation Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Thalys Medical Technology Group Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Thalys Medical Technology Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Factbox-Unions vs Macron: French pension strikes snarl trains, close schools RE
Angze Taiying No. 6 Private Equity Securities Investment, managed by Shanghai Angze Private Fund Management Co., Ltd. completed the acquisition of a 6.88% stake in Thalys Medical Technology Group Inc. from Saihai Health Technology Co., Ltd. CI
Angze Taiying No. 6 Private Equity Securities Investment, managed by Shanghai Angze Private Fund Management Co., Ltd. signed Share Transfer Agreement to acquire 6.88% stake in Thalys Medical Technology Group Inc. from Saihai Health Technology Co., Ltd. for CNY 160 million. CI
Thalys Medical Technology Group Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Thalys Medical Technology Group Inc. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
More news
1 day+6.04%
1 week-24.30%
Current month+7.60%
1 month-0.37%
3 months-24.86%
6 months-29.40%
Current year-27.23%
More quotes
1 week
7.47
Extreme 7.47
10.25
1 month
7.06
Extreme 7.06
11.59
Current year
5.20
Extreme 5.2
11.59
1 year
5.20
Extreme 5.2
15.98
3 years
5.20
Extreme 5.2
23.00
5 years
5.20
Extreme 5.2
30.86
10 years
5.20
Extreme 5.2
47.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 21-08-18
Director of Finance/CFO 47 23-01-19
Chairman 55 12-07-21
Members of the board TitleAgeSince
Chairman 55 12-07-21
Director/Board Member 59 12-07-21
Director/Board Member 43 12-07-21
More insiders
Date Price Change Volume
24-03-28 8.07 +6.04% 26,904,900
24-03-27 7.61 -9.40% 25,997,050
24-03-26 8.4 -4.98% 39,597,100
24-03-25 8.84 -6.65% 29,681,140
24-03-22 9.47 -9.98% 43,682,480

End-of-day quote Shanghai S.E., March 27, 2024

More quotes
Thalys Medical Technology Group Inc., formerly Thalys Medical Technology Inc., is a China-based company principally engaged in the provision of intensified distribution business and simple sales business and the research, design, manufacture and distribution of independent in vitro diagnostic products. Its product type includes purchased reagents and consumables, self-produced reagents and consumables, as well as purchased equipment. The Company mainly operates its business in domestic markets, with Hubei, Hunan, Jiangsu, Henan and Shanghai province as its major markets.
More about the company
  1. Stock
  2. Equities
  3. Stock Thalys Medical Technology Group Corporation - Shanghai S.E.